The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted ... If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid (BP) in the ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults and pediatric patients with diabetes mellitus. The regulatory ...

While AI will not replace health care providers, it will change how medicine is practiced, emphasizing the need for human oversight and ethical considerations. This summary was automatically ...

Paris: Sanofi has announced the acquisition of 2.3% of its shares from long-standing shareholder L’Oréal. This transaction is part of Sanofi’s share buyback program announced on January 30, 2025. It ...

Recently, Sanofi-Aventis US LLC filed a lawsuit against the Department of Health and Human Services (HHS) and the Health Resources… Subscribe To Our Daily News Sign up here to get the latest news and ...

Sanofi’s proposed changes would require 340B-covered entities ... Thomas Sullivan is Editor of Policy and Medicine. Senior Vice President at Clinical Education Alliance (CEA) a leading continuing ...